Genprex Gapping on Non-Human Primate Type 1 Diabetes study data

February 23, 2023

(24/7 MARKET NEWS) – Genprex, Inc. (NASDAQ:GNPX) announced, this morning, that data highlighting the potential of its Type 1 diabetes gene therapy results show statistically significant decreases in insulin requirements, increases in c-peptide levels and improvements in glucose tolerance compared to baseline. The data will be presented by its research collaborators at the University of Pittsburgh at the 16th International Conference on Advanced Technologies & Treatments for Diabetes taking place February 22-25, 2023 in Berlin, Germany.

Genprex is at $1.70, up $0.06 (+3.66%), on trading volume of 2.6 million premarket shares.

Its 52-week trading range is $0.97 to $2.67. It popped and hit $2.14 just after this morning’s announcement, but it pulled back and its next key inflection point is $1.79.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.